 Shares of Marinus Pharmaceuticals Inc. MRNS, 4.13 gained 7.9 in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for 110 million to Novo Nordisk NVO, 1.19 . Marinus CFO Steven Pfanstiel told investors in a news release that the sale extends our cash runway into the fourth quarter of 2023. 